

# Colorectal Cancer Drugs Market In 2029

*The Business Research Company's  
Colorectal Cancer Drugs Market In 2029*

LONDON, GREATER LONDON, UNITED KINGDOM, December 4, 2025 /EINPresswire.com/ -- "Colorectal Cancer Drugs Market to Surpass \$17 billion in 2029. In comparison, the oncology drugs market, which is considered as its parent market, is expected to be approximately \$411 billion by 2029, with colorectal cancer drugs to represent around 4% of the parent market. Within the broader pharmaceuticals industry, which is expected to be \$2,355 billion by 2029, the colorectal cancer drugs market is estimated to account for nearly 1% of the total market value.


**Which Will Be the Biggest Region in the Colorectal Cancer Drugs Market in 2029?**

North America will be the largest region in the colorectal cancer drugs market in 2029, valued at \$7,236 million. The market is expected to grow from \$5,658 million in 2024 at a compound annual growth rate (CAGR) of 5%. The strong growth can be attributed to the growing adoption of combination therapies and the rising aging population.

**Which Will Be The Largest Country In The Global Colorectal Cancer Drugs Market In 2029?**

The USA will be the largest country in the colorectal cancer drugs market in 2029, valued at \$6,632 million. The market is expected to grow from \$5,194 million in 2024 at a compound annual growth rate (CAGR) of 5%. The strong growth can be attributed to the growing adoption of combination therapies and strategic partnerships.

Request a free sample of the Colorectal Cancer Drugs Market report:



[https://www.thebusinessresearchcompany.com/sample\\_request?id=2590&type=smp](https://www.thebusinessresearchcompany.com/sample_request?id=2590&type=smp)

What will be Largest Segment in the Colorectal Cancer Drugs Market in 2029?

The colorectal cancer drugs market is segmented by cancer type into colorectal adenocarcinoma, gastrointestinal carcinoid tumors and other cancer types. The colorectal adenocarcinoma market will be the largest segment of the colorectal cancer drugs market segmented by cancer type accounting, for 91% or \$15,549 million of the total in 2029. The colorectal adenocarcinoma market will be supported by increasing incidence of colorectal adenocarcinoma worldwide, rising demand for targeted and personalized therapies, ongoing advancements in precision medicine, growing adoption of immunotherapies and combination regimens and expanding investments in clinical research and drug development for colorectal cancer treatment.

“

Expected to grow to \$27.01 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%”


*The Business Research Company*

The colorectal cancer drugs market is segmented by class into targeted therapy, immunotherapy, chemotherapy and other classes. The chemotherapy market will be the largest segment of the colorectal cancer drugs market segmented by class accounting for 42% or \$7,206 million of the total in

2029. The chemotherapy market will be supported by increasing prevalence of colorectal cancer, widespread clinical adoption of standard-of-care cytotoxic agents, ongoing improvements in drug formulations and delivery methods, rising demand for combination therapy regimens and continued investment in research to enhance efficacy and reduce side effects.

The colorectal cancer drugs market is segmented by distribution channels into hospital pharmacies, retail pharmacies and other distribution channels. The hospitals pharmacies market will be the largest segment of the colorectal cancer drugs market segmented by distribution channels accounting for 48% or \$8,274 million of the total in 2029. The hospitals pharmacies market will be increasing number of hospital admissions for colorectal cancer treatment, growing adoption of advanced therapies such as targeted drugs and immunotherapies, integration with multidisciplinary oncology departments, rising focus on patient safety and medication management and expanding investments in hospital-based oncology pharmacy services.

What is the expected CAGR for the Colorectal Cancer Drugs Market leading up to 2029?  
The expected CAGR for the colorectal cancer drugs market leading up to 2029 is 5%.



## What Will Be The Growth Driving Factors In The Global Colorectal Cancer Drugs Market In The Forecast Period?

The rapid growth of the global colorectal cancer drugs market leading up to 2029 will be driven by the following key factors that are expected to reshape clinical pathways, drug manufacturing, quality assurance, and supply-chain operations worldwide.

**Rise In Aging Population** - The rise in aging population will become a key driver of growth in the colorectal cancer drugs market by 2029. Older individuals face a higher risk of developing colorectal cancer due to factors such as age-related genetic mutations, long-term lifestyle influences and a decline in immune function. As the global population aged 60 and above continues to expand, the incidence of colorectal cancer is projected to rise accordingly, fueling increased demand for effective treatment options. This demographic trend also highlights the need for treatment approaches specifically designed for elderly patients, who often have comorbidities and greater sensitivity to drug toxicity. In response, healthcare systems are placing greater emphasis on geriatric oncology, enhanced screening efforts and preventive measures to address the growing cancer burden among older adults. As a result, the rise in aging population is anticipated to contribute to a 2.0% annual growth in the market.

**Increasing Awareness And Screening Programs** - The increasing awareness and screening programs will emerge as a major factor driving the expansion of the market by 2029. Early detection through organized screening initiatives greatly enhances treatment outcomes and boosts demand for effective therapies. Colorectal cancer drugs tend to be more effective when administered during the early stages of the disease, underscoring the importance of timely diagnosis. In addition, government-backed programs and public health campaigns play a crucial role in educating communities about risk factors, symptoms and the value of regular screening, encouraging individuals to seek early medical intervention. As these efforts increase screening coverage—especially in regions that previously had limited access to cancer diagnostics—the demand for colorectal cancer treatments is projected to rise, contributing to overall market expansion. Consequently, the Increasing Awareness And Screening Programs is projected to contribute to a 1.0% annual growth in the market.

**Growing Use Of Combination Therapies** - The growing use of combination therapies will serve as a key growth catalyst for the market by 2029. These treatment approaches, which involve the use of two or more therapeutic agents, are gaining traction due to their ability to enhance efficacy, delay drug resistance and improve survival outcomes—particularly in patients with advanced-stage disease. In colorectal cancer, combining chemotherapy, targeted therapies and immunotherapies offers a more robust and comprehensive strategy, especially for those who do not respond well to monotherapy. This shift is further supported by clinical evidence showing improved progression-free survival among patients receiving combination regimens. Additionally, pharmaceutical companies are actively expanding their clinical pipelines to develop and test new drug combinations, often tailored to specific genetic subtypes of colorectal cancer. As oncologists and healthcare systems continue to emphasize multidrug strategies to optimize

patient outcomes, the growing reliance on combination therapies is poised to be a key driver of demand in the colorectal cancer drugs market throughout the forecast period. Therefore, this growing use of combination therapies is projected to supporting to a 0.7% annual growth in the market.

**Increasing Healthcare Expenditure** - The increasing healthcare expenditure will become a significant driver contributing to the growth of the market by 2029. Increased spending allows governments and healthcare systems to invest more heavily in cancer care, including the procurement of advanced drug therapies, improved diagnostic tools and comprehensive patient support services. Enhanced funding also contributes to better hospital infrastructure and expanded treatment capacity, enabling more patients to access timely and effective care. Furthermore, higher healthcare budgets support the rollout of national screening programs and early detection initiatives, which lead to an increase in diagnosed cases entering the treatment pipeline. With a growing focus on precision medicine, increased expenditure also facilitates the adoption of cutting-edge targeted therapies and immunotherapies, many of which are costlier than traditional treatments. As countries continue to prioritize healthcare investment to address the rising burden of chronic illnesses like cancer, this upward trend in healthcare spending is poised to be a key driver of demand in the colorectal cancer drugs market throughout the forecast period. Consequently, the Increasing Healthcare Expenditure is projected to contributing to a 0.5% annual growth in the market.

Access the detailed Colorectal Cancer Drugs Market report here:

<https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report>

**What Are The Key Growth Opportunities In The Colorectal Cancer Drugs Market in 2029?**

The most significant growth opportunities are anticipated in the colorectal adenocarcinoma drugs market, the colorectal cancer target therapy drugs market and the hospital-based colorectal cancer drugs market. Collectively, these segments are projected to contribute over \$7 billion in market value by 2029, driven rising global incidence rates of colorectal malignancies, increasing adoption of targeted and immunotherapy-based treatments, and the growing integration of precision oncology approaches. This surge reflects the rapid advancement in biomarker-driven drug development, enhanced diagnostic capabilities, and expanding clinical research initiatives that are transforming the landscape of colorectal cancer therapeutics and driving sustained growth within the broader oncology treatment ecosystem.

The colorectal adenocarcinoma drugs market is projected to grow by \$3,572 million, the hospital-based colorectal cancer drugs market by \$1,763 million, and the colorectal cancer target therapy drugs market by \$1,439 million over the next five years from 2024 to 2029.

**Learn More About The Business Research Company**

The Business Research Company ([www.thebusinessresearchcompany.com](https://www.thebusinessresearchcompany.com)) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. We

have published over 17,500 reports across 27 industries and 60+ geographies. Our research is powered by 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

We provide continuous and custom research services, offering a range of specialized packages tailored to your needs, including Market Entry Research Package, Competitor Tracking Package, Supplier & Distributor Package and much more.

Disclaimer: Please note that the findings, conclusions and recommendations that TBRC Business Research Pvt Ltd delivers are based on information gathered in good faith from both primary and secondary sources, whose accuracy we are not always in a position to guarantee. As such TBRC Business Research Pvt Ltd can accept no liability whatever for actions taken based on any information that may subsequently prove to be incorrect. Analysis and findings included in TBRC reports and presentations are our estimates, opinions and are not intended as statements of fact or investment guidance.

Contact Us:

The Business Research Company

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email: [info@tbrc.info](mailto:info@tbrc.info)

Follow Us On:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>"

Oliver Guirdham

The Business Research Company

+44 7882 955267

[info@tbrc.info](mailto:info@tbrc.info)

Visit us on social media:

[LinkedIn](#)

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/872154635>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.